On 16 May 2025, the FDA cleared the first blood-based test for diagnosing Alzheimer’s disease—a major shift in how we detect the condition. Developed by Fujirebio Diagnostics, the Lumipulse test offers a simpler, faster, and less invasive alternative to PET scans and spinal taps, bringing early detection within easier reach for patients showing signs of cognitive decline. 

After writing the last post on Misunderstanding Dementia – A Common Issue, I have developed more passion to share the awareness of Dementia.